Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier

Molecular Medicine

Volumn 17, Issue 3-4, 2011, Pages 149-162

  Paris, Daniel ^a   Bachmeier, Corbin ^a   Patel, Nikunj ^a   Quadros, Amita ^a   Volmar, Claude Henry ^a   Laporte, Vincent ^a   Ganey, Jim ^a   Beaulieu Abdelahad, David ^a   Ait Ghezala, Ghania ^a   Crawford, Fiona ^a   Mullan, Michael J ^a  

^a ROSKAMP INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMYLOID BETA PROTEIN; BETA SECRETASE; DILTIAZEM; FELODIPINE; ISRADIPINE; NIFEDIPINE; NILVADIPINE; NIMODIPINE; NITRENDIPINE; PLACEBO; VERAPAMIL;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TARGETING; TRANSGENE;

ALZHEIMER DISEASE; AMLODIPINE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; CALCIUM CHANNEL BLOCKERS; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAZE LEARNING; MEMORY; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; NIFEDIPINE; NITRENDIPINE;

EID: 79952860789     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00180     Document Type: Article

References (57)

1. Perl DP. (2010) Neuropathology of Alzheimer's disease. Mt. Sinai J. Med. 77:32-42.
2. Chow VW, Mattson MP, Wong PC, Gleichmann M. (2010) An overview of APP processing enzymes and products. Neuromolecular Med. 12:1-12.
3. Lublin AL, Gandy S. (2010) Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. Mt. Sinai J. Med. 77:43-49.
4. Gleichmann M, Mattson MP. (2010) Alzheimer's disease and neuronal network activity. Neuromolecular Med. 12:44-47.
5. Citron M. (2010) Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug. Discov. 9:387-398.
6. Vassar R, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:735-741.
7. Forette F, et al. (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 352:1347-1351.
8. Forette F, et al. (2002) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst- Eur) study. Arch. Intern. Med. 162:2046-2052.
9. Hanon O, Forette F. (2004) Prevention of dementia: lessons from SYST-EUR and PROGRESS. J. Neurol. Sci. 226:71-74.
10. Hanyu H, et al. (2007) Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int. J. Geriatr. Psychiatry. 22:1264-1266.
11. Matsuda H, et al. (2008) Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. Clin. Nucl. Med. 33:34-35.
12. Sato T, et al. (2008) A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists. Nippon Ronen Igakkai Zasshi. 45:428-433.
13. Khachaturian AS, et al. (2006) Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63:686-692.
14. Yasar S, Corrada M, Brookmeyer R, Kawas C. (2005) Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol. Aging. 26:157-163.
15. Duron E, Hanon O. (2010) Antihypertensive treatments, cognitive decline, and dementia. J. Alzheimers Dis. 20:903-914.
16. Fournier A, et al. (2009) Prevention of dementia by antihypertensive drugs: how AT1-receptorblockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother. 9:1413-1431.
17. Bellew KM, et al. (2004) Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis. Assoc. Disord. 18:208-213.
18. SHEP Cooperative Research Group. (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 265:3255-3264.
19. Maxwell CJ, Hogan DB, Ebly EM. (1999) Calcium- channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 161:501-506.
20. Koo EH, Squazzo SL. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269:17386-17389.
21. Paris D, et al. (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation. 7:17.
22. Holcomb L, et al. (1998) Accelerated Alzheimertype phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:97-100.
23. Bachmeier C, Mullan M, Paris D. (2010) Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology. 2010;62:519-529.
24. Yuan W, Li G, Gil ES, Lowe TL, Fu BM. (2010) Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann. Biomed. Eng. 38:1463-1472.
25. Methia N, et al. (2001) ApoE deficiency compromises the blood brain barrier especially after injury. Mol. Med. 7:810-815.
26. Epiphanio S, et al. (2010) VEGF promotes malaria- associated acute lung injury in mice. PLoS Pathog. 6:e1000916.
27. Hsiao K, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
28. Morris R. (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 11:47-60.
29. Furukawa T, et al. (1999) Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 291:464-473.
30. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. (1997) Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 61:2083-2090.
31. Nag S, Picard P, Stewart DJ. (2001) Expression of nitric oxide synthases and nitrotyrosine during blood-brain barrier breakdown and repair after cold injury. Lab. Invest. 81:41-49.
32. Janus C, et al. (2000) Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes. Neurobiol. Aging. 21:541-549.
33. Hanon O, et al. (2006) Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J. Hypertens. 24:2101-2107.
34. Mann GE, Zlokovic BV, Yudilevich DL. (1985) Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim. Biophys. Acta. 819:241-248.
35. Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakic L. (1985) Permeability of the bloodcerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Res. 358:191-199.
36. Deane R, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9:907-913.
37. Shibata M, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor- related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489-1499.
38. Iwasaki Y, et al. (2004) Nilvadipine inhibits nuclear factor-kappaB-dependent transcription in hepatic cells. Clin. Chim. Acta. 350:151-157.
39. Kagawa H, Nomura S, Ozaki Y, Nagahama M, Fukuhara S. (1999) Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension. Clin. Exp. Hypertens. 21:1177-1188.
40. Tanaka N, et al. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275:25781-25790.
41. Penzo M, et al. (2010) Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J. Immunol. 184:4497-4509; erratum 184:7314.
42. Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK. (2004) Gene structure and organization of the human beta-secretase (BACE) promoter. Faseb J. 18:1034-1036.
43. Buggia-Prevot V, Sevalle J, Rossner S, Checler F. (2008) NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J. Biol. Chem. 283:10037-10047.
44. Marx N, et al. (2004) Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes. 53:2662-2668.
45. Guglielmotto M, et al. (2010) AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol. Aging. 2010, Jul 16 [Epub ahead of print].
46. Paris D, et al. (2007) Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci. Lett. 415:11-16.
47. Paris D, et al. (2004) Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 999:53-61.
48. Iwasaki K, et al. (2007) Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol. Pharm. Bull. 30:698-701.
49. Kennelly S, et al. APOE ε4 specific short-term cognitive benefits of nilvadipine intervention in Alzheimer's patients in an open-label trial. Ther. Adv. Neurol. Disord. Accepted July 2010.
50. Iwata N, et al. (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6:143-150.
51. Monro OR, et al. (2002) Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol. Aging. 23:405-412.
52. Deane R, et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43:333-344.
53. Bell RD, Zlokovic BV. (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta. Neuropathol. 118:103-113.
54. Deane R, Bell RD, Sagare A, Zlokovic BV. (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets. 8:16-30.
55. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. (2000) Clearance of amyloid betapeptide from brain: transport or metabolism? Nat. Med. 6:718-719.
56. Mawuenyega KG, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 330:1774.
57. Bateman RJ, et al. (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12:856-861.